Proove Biosciences Presented Research and Data on How Genetic Testing Can Improve Pain Medicine Selection and Dosing

Proove Biosciences was the only company presenting evidence-based research on how genetic testing can improve efficiency and effectiveness of cancer pain management.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
In the emerging field of pain medicine genetics, Proove is far outpacing other labs who continue to market run-of-the-mill drug metabolism genetic testing. - Brian Meshkin, CEO, Proove Biosciences

Irvine, CA (PRWEB) April 29, 2014

Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented clinical data on how proprietary genetic tests have been helping physicians improve patient pain treatment outcomes this weekend at The Valley Cancer Pain Foundation’s Third Annual Cancer Pain Conference. Proove is the only company exhibiting data on how company research and methods have been allowing doctors to utilize genetic analysis to make safer and more effective pain medication selection and dosing. At this week’s session, Proove Clinical Science Liaison, Derrick Holman, MD presented Proove research and provided medical education on the genetics of pain medicine.

“As the only company presenting data on how genetic tests can improve the efficiency of pain medication and treatment, we were glad to participate in this weekends conference,” stated Brian Meshkin, CEO and founder of Proove Biosciences. “The Valley Cancer Pain Foundation does a wonderful job of providing an educational opportunity for pain clinicians, anesthesiologists, neurosurgeons, and hospice providers to learn about new technologies and best practices available in treating pain.”

The annual conference is an industry gathering that aims to promote the most recent and relevant data and treatment options, and provide a forum to interact and discuss new and emerging evidence-based methods of improving access to and quality of care.

Proove continues to display industry leadership by publishing research showing how our unique genetic testing capabilities improve patient care. In the emerging field of pain medicine genetics, Proove is far outpacing other labs who continue to market run-of-the-mill drug metabolism genetic testing,” stated Meshkin.

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).


Contact